{"id":"NCT02407236","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-10","primaryCompletion":"2018-08-10","completion":"2021-11-30","firstPosted":"2015-04-02","resultsPosted":"2019-12-23","lastUpdate":"2025-04-29"},"enrollment":961,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":null},"conditions":["Colitis, Ulcerative","Inflammatory Bowel Diseases"],"interventions":[{"type":"DRUG","name":"Placebo IV","otherNames":[]},{"type":"DRUG","name":"Placebo SC","otherNames":[]},{"type":"DRUG","name":"Ustekinumab IV","otherNames":[]},{"type":"DRUG","name":"Ustekinumab SC","otherNames":[]}],"arms":[{"label":"Induction Study - Placebo Intravenous (IV)","type":"PLACEBO_COMPARATOR"},{"label":"Induction Study - Ustekinumab 130 milligram (mg) IV","type":"EXPERIMENTAL"},{"label":"Induction Study - Ustekinumab 6 mg/kg IV","type":"EXPERIMENTAL"},{"label":"Induction Study- Placebo- Nonresponsders at Week 8","type":"OTHER"},{"label":"Induction study-Ustekinumab Nonresponders at Week 8","type":"OTHER"},{"label":"Maintenance Study - Placebo Subcutaneous (SC)","type":"PLACEBO_COMPARATOR"},{"label":"Maintenance Study - Ustekinumab 90mg SC every 12 weeks","type":"EXPERIMENTAL"},{"label":"Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w)","type":"EXPERIMENTAL"},{"label":"Maintenance Study - Placebo IV - Responder - Placebo SC","type":"OTHER"},{"label":"Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w","type":"OTHER"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of ustekinumab as intravenous (IV: into the vein) infusion in induction study in participants with moderately to severely active Ulcerative Colitis (UC) and as subcutaneous (SC) administration in maintenance study in participants with moderately to severely active Ulcerative Colitis (UC) who have demonstrated a clinical response to Induction treatment with IV ustekinumab.","primaryOutcome":{"measure":"Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition)","timeFrame":"Week 8","effectByArm":[{"arm":"Induction Study (IS): Placebo Intravenous (IV)","deltaMin":17,"sd":null},{"arm":"IS: Ustekinumab 130 Milligram (mg) IV","deltaMin":50,"sd":null},{"arm":"IS: Ustekinumab Approximately 6 mg/kg IV","deltaMin":50,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG002","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":247,"countries":["United States","Australia","Austria","Belgium","Bulgaria","Canada","Czechia","Denmark","France","Germany","Hungary","Israel","Japan","Netherlands","New Zealand","Poland","Romania","Russia","Serbia","Slovakia","South Korea","Ukraine","United Kingdom"]},"refs":{"pmids":["40668079","39368474","38310565","38095692","38025971","35276329","33086438","32964215","32853634","31553833"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":319},"commonTop":["Colitis Ulcerative","Nasopharyngitis","Headache","Arthralgia","Upper Respiratory Tract Infection"]}}